All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Ide-cel in triple-class RRMM: Key efficacy and safety data from the KarMMa trial

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Albert Oriol, Catalan Institute of Oncology, Barcelona, ES. We asked, What are the key efficacy and safety data from the KarMMa trial?

Oriol begins by highlighting that the KarMMa trial evaluates the efficacy of idecabtagene vicleucel (ide-cel), which represents the first CAR T-cell therapy approved in multiple myeloma. He reviews and compares CAR T-cell therapy with other treatment options, such as immunotherapy.